Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Upfront surgery and pathological stage based adjuvant chemoradiation strategy in locally advanced esophageal squamous cell carcinoma (216P)

Date

18 Nov 2017

Session

Poster lunch

Presenters

Po-Kuei Hsu

Citation

Annals of Oncology (2017) 28 (suppl_10): x57-x76. 10.1093/annonc/mdx660

Authors

P. Hsu

Author affiliations

  • Surgery, Taipei Veterans General Hospital, 11217 - Taipei/TW
More

Resources

Background

Adjuvant chemoradiation is reported to have survival benefit for esophageal squamous cell carcinoma (ESCC). We aim to evaluate the “upfront surgery and pathological stage based adjuvant chemoradiation” strategy, in which adjuvant therapy is guided by pathological stage, in locally advanced ESCC.

Methods

Data of 2976 clinical stage II/III ESCC patients, including 1735 in neoadjuvant chemoradiation and 1241 in upfront surgery groups, was obtained from a nationwide database. Pretreatment tumor factors and patient comorbidities were included in the propensity score matching to identify 562 well-balanced pairs for outcome comparison. Patients in upfront surgery group was further categorized into the “upfront surgery and pathological stage based adjuvant chemoradiation” and “upfront surgery only” groups.

Results

The 3-year overall survival (OS) rates in “neoadjuvant chemoradiation”, “upfront surgery and pathological stage based adjuvant chemoradiation”, and “upfront surgery only” groups were 41.5%, 45.8%, and 28.5%, respectively. The “upfront surgery and pathological stage based adjuvant chemoradiation” strategy was not a significant prognostic factor (hazard ratio: 1.12; 95% confidence interval: 0.94-1.33, p = 0.195) compared to the “neoadjuvant chemoradiation” group in the multivariable analysis. In propensity score matched patients, the 3-year OS rate was 41.7% in neoadjuvant chemoradiation group, compared to 35.6% in the “upfront surgery and pathological stage based adjuvant chemoradiation” group (p = 0.147), and 20.3% in the “upfront surgery only” group (p < 0.001).

Conclusions

No survival difference was observed between the “neoadjuvant chemoradiation followed by surgery” protocol and the “upfront surgery and pathological stage based adjuvant chemoradiation” strategy.

Clinical trial identification

Legal entity responsible for the study

Taipei Veterans General Hospital

Funding

None

Disclosure

The author has declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings